The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2025 | ARTEMIDE-HCC01: first-line rilvegostomig plus bevacizumab in uHCC
Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, comments on the rationale and design of the Phase III ARTEMIDE-HCC01 trial (NCT06921785) assessing rilvegostomig plus bevacizumab, with or without tremelimumab, as first-line therapy for unresectable hepatocellular carcinoma (uHCC). The study explores whether dual or triple immune checkpoint blockade combined with anti-angiogenic therapy can improve outcomes versus atezolizumab plus bevacizumab. This interview took place at 2025 European Society for Medical Oncology (ESMO) Asia Congress in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the ARTEMIDE-HCC01 study is a trial in progress. The title was a phase 3 study of the rilvegostomig in combination with bevacizumab with or without tremelimumab as the first-line treatment for the HCC. The rilvegostomig is a bispecific antibody against the TIGIT and the PD-L1, while the bevacizumab is an anti-VEGF antibody. Tremelimumab is the CTLA-4 antibody. So those patients with locally advanced or metastatic and or the unresected HCC with a preserved hepatic function and also the equal performance status of zero or one were recruited in this study...
So the ARTEMIDE-HCC01 study is a trial in progress. The title was a phase 3 study of the rilvegostomig in combination with bevacizumab with or without tremelimumab as the first-line treatment for the HCC. The rilvegostomig is a bispecific antibody against the TIGIT and the PD-L1, while the bevacizumab is an anti-VEGF antibody. Tremelimumab is the CTLA-4 antibody. So those patients with locally advanced or metastatic and or the unresected HCC with a preserved hepatic function and also the equal performance status of zero or one were recruited in this study. There was three arms in this study. The control arm, which is the arm C, is the atezolizumab and bevacizumab, which is the current standard as the first-line treatment for liver cancer. There were two experimental arms. The arm A was the tremelimumab together with the rivogastigimab and the bevacizumab, while the arm B was the rivogastigimab and the bevacizumab without the addition of tremelimumab. So basically, this study is testing the potential role of adding the CTLA-4 on the TIGIT and the VEGF combinations in the treatment of HCC. And also, as mentioned, there’s another experimental arm which only tested the TIGIT, PD-L1, and bevacizumab. The potential result is that this study may bring a new standard of treatment with potentially higher response rate, better overall survival, and progression-free survival for the patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
